News

Mr Henley joins Medicure from a private investment and management company where he held the position of vice president of finance. Prior to that Mr Henley’s was vice-president

Robert Kluge, corporate senior vice president of Varian, said: “This contract marks the latest chapter in our 30-year relationship with Toshiba Medical Systems. We have complementary design engineering

Of the first six evaluable patients in this Phase II trial one patient has had a confirmed objective response, as measured by Recist criteria. As part of the

The license provides Novartis with access to BioWa’s Potelligent technology platform to research, develop, manufacture, and commercialize antibody-dependent cellular cytotoxicity (ADCC)-enhanced antibodies for an undisclosed number of targets.

Under the terms of the settlement agreement, the litigation, which was pending before the US District Court of California, has now been fully resolved and dismissed. The settlement

The trial is for Aegera’s AEG35156, a targeted therapy for blood cancer patients with follicular lymphoma, small lymphocytic lymphoma and chronic lymphocytic leukemia. The clinical trials will take

The most advanced drug in the portfolio is expected to enter a Phase II clinical study later this year. The Phase II candidate and all other drugs in

This 12-month treatment period was an open label extension to a three- month efficacy trial which has already reported, showing that Bronchitol improved quality of life and mucus

The license is based on a suite of issued and pending Johns Hopkins University patents covering imprinting abnormalities of the insulin-like growth factor 2 gene (IGF2). Orion’s simple